BenzingaAugust 7, 2026 at 3:37 PM NY2 Months Ago
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34
UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
